CAR T Cell Clinical Trials
City of Hope’s comprehensive chimeric antigen receptor (CAR) T cell therapy program is addressing some of the hardest-to-treat cancers by accelerating innovative clinical research approaches.
For all CAR T inquiries (patient, physician and clinical trials)
Media inquiries
800-888-5323
[email protected]
[email protected]
Ongoing Trials
Ongoing CAR T clinical research initiated at City of Hope includes trials in:
Solid Tumors
- Brain tumors (glioblastoma, ependymoma or medulloblastoma) — IRB #19497
Brain tumor-specific immune cells (IL13Ralpha2-CAR T Cells) for the treatment of leptomeningeal glioblastoma, ependymoma or medulloblastoma
PI: Lisa Feldman, M.D. - Pediatric brain tumors — IRB #19130
Phase I study of cellular immunotherapy using memory-enriched T cells lentivirally transduced to express an IL13Ra2-TARGETING, hinge-optimized, 41BB-costimulatory chimeric receptor and a truncated CD19 for children with recurrent/refractory malignant brain tumors
PI: Leo Wang, M.D. - Brain cancer (glioblastoma) — IRB #19309
CAR T cells with a chlorotoxin tumor-targeting domain for the treatment of MPP2+ recurrent or progressive glioblastoma
PI: Behnam Badie, M.D. - Brain cancer (glioblastoma) — IRB #18251
IL13Ralpha2-targeted CAR T cells with or without nivolumab and ipilimumab in treating patients with recurrent or refractory glioblastoma
PI: Behnam Badie, M.D. - Brain cancer (glioma) — IRB#16064
Memory-enriched T cells in treating patients with recurrent or refractory grade III-IV glioma
PI: Behnam Badie, M.D. - HER2-positive breast cancer that has metastasized to the brain — IRB #17237
HER2-CAR T cells in treating participants with brain or leptomeningeal metastases
PI: Jana Portnow, M.D. - Prostate cancer — IRB #17483
PSCA-CAR T cells in treating patients with PSCA+ metastatic castration-resistant prostate cancer
PI: Tanya Dorff, M.D. - IRB #13384
Phase I study of cellular immunotherapy using central memory-enriched T cells lentivirally transduced to express an IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR and a truncated CD19 for patients with recurrent/refractory malignant glioma
Blood Cancers
- Leukemia
- ALL — IRB #13447
Cellular immunotherapy in treating patients with high-risk acute lymphoblastic leukemia
PI: Samer K. Khaled, M.D. - AML and blastic plasmacytoid dendritic cell neoplasm [BPDCN]) — IRB #13272
Genetically modified T cell immunotherapy in treating patients with relapsed/refractory acute myeloid leukemia and persistent/recurrent blastic plasmacytoid dendritic cell neoplasm
PI: Elizabeth Lihua Budde, M.D., Ph.D.
- ALL — IRB #13447
- Lymphoma and leukemia
Partner Trials
City of Hope is partnering with global biopharmaceutical companies on the following ongoing trials:
Solid Tumors
- Prostate cancer — IRB #19603
P-PSMA-101 CAR T cells in the treatment of subjects with metastatic castration-resistant prostate cancer (mCRPC)
PI: Tanya Dorff, M.D. - Sarcoma — IRB #19194
A Phase 2 single arm, open-label clinical trial of ADP-A2M4 SPEAR™ T cells in subjects with advanced synovial sarcoma or myxoid/round cell liposarcoma
PI: Warren A. Chow, M.D. - Sarcoma — NCT01343043
A pilot study of genetically engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ patients with synovial sarcoma (NY-ESO-1)
City of Hope
PI: Warren A. Chow, M.D. - Solid tumor — IRB #19292
Master protocol to assess the safety and antitumor activity of genetically engineered T cells in NY-ESO-1 and/or LAGE-1a positive solid tumors
PI: Warren A. Chow, M.D. - Solid tumors (anus, breast, colon, melanoma/skin, ovary, prostate, rectum and urinary bladder) — IRB #19223
PACT-0101 NeoTCR-P1 with or without anti-PD-1 in locally advanced or metastatic solid tumors
PI: Mihaela Cristea, M.D.
Blood Cancers
- Diffuse large B cell lymphoma — NCT02631044
Study evaluating the safety and pharmacokinetics of JCAR017 in B cell Non-Hodgkin lymphoma
PI: Tanya Siddiqi,M.D. - DLBCL — IRB #19307
A Single-arm, open-label, multi-centre, Phase I/II study evaluating the safety and clinical activity of AUTO3, a CAR T cell treatment targeting CD19 and CD22 with anti-PD1 antibody in patients with relapsed or refractory diffuse large B cell lymphoma
PI: Elizabeth Lihua Budde, M.D., Ph.D. - Large B Cell Lymphoma — IRB #19091
A Phase 2 open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide in subjects with refractory large B cell lymphoma (ZUMA-14)
PI: Elizabeth Lihua Budde, M.D., Ph.D. - Lymphoma — IRB #18344
Efficacy and safety of axicabtagene ciloleucel as first-line therapy in participants with high-risk large B cell lymphoma (ZUMA-12)
PI: Alex Herrera, M.D. - Lymphoma — IRB #18101
A multicenter, open-label, expanded access study of axicabtagene ciloleucel for the treatment of subjects with relapsed/refractory large B cell lymphoma
PI: Elizabeth Lihua Budde, M.D., Ph.D. - Multiple myeloma — NCT03168438
NY-ESO-1c259T alone and in combination with pembrolizumab for multiple myeloma
PI: Maung Myo Htut, M.D. - Myeloma — IRB #20059
A dose-escalation study to evaluate the safety and clinical activity of PBCAR269A in study participants with relapsed/refractory multiple myeloma
PI: Maung Myo Htut, M.D. - NHL/ALL — IRB #18388
Phase 1/2a, open-label, dose-escalation/expansion, parallel assignment study to evaluate the safety and clinical activity of PBCAR0191 in subjects with relapsed/refractory Non-Hodgkin lymphoma and B cell acute lymphoblastic leukemia
PI: Anthony Stein, M.D. - NHL/CLL/SLL — IRB #20075
A Phase 1/2a, open-label, dose-escalation/expansion, parallel assignment study to evaluate the safety and clinical activity of PBCAR20A in study participants with relapsed/refractory Non-Hodgkin lymphoma or chronic lymphocytic leukemia or small lymphocytic lymphoma
PI: Geoffrey Shouse, D.O., Ph.D. - Peds ALL — IRB #19376
A Phase II trial of tisagenlecleucel in first-line high-risk pediatric and young adult patients with B cell acute lymphoblastic leukemia who are minimal residual disease positive at the end of consolidation therapy
PI: Anna Pawlowska, M.D. - Peds ALL and DLBCL — IRB #19396
Managed access program to provide access to CTL019, for ALL or DLBCL patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
PI: Elizabeth Lihua Budde, M.D., Ph.D. - BPDCN/AML/MDS — IRB #19092
A Phase 1/2, open-label, multicenter trial to assess the safety and efficacy of MB-102 in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and high-risk myelodysplastic syndrome
PI: Elizabeth Lihua Budde, M.D., Ph.D.
New Trials
Blood Cancers
- The rare disease amyloidosis
Preclinical Research
City of Hope is also conducting preclinical CAR T cell therapy research in solid tumors for ovarian, head and neck, cervical and pancreatic cancers.